Table 1 Baseline clinical characteristics

From: CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study

  

CHADS 2

CHA 2 DS 2 -VASc

 

Total

Low

Intermediate

High

Low

Intermediate

High

Number

1221

186 (15.2%)

283 (23.2%)

752 (61.6%)

53 (4.3%)

163 (13.4%)

1005 (82.3%)

Observation period, months

19.4 (13.8–23.3)

17.4 (13.3–23.0)

18.6 (13.1–23.2)

20.9 (14.2–23.6)†

17.2 (10.6–22.8)

17.9 (13.6–23.0)

20.2 (13.8–23.4)*

Age, years

70±10

63±9

69±10

72±8†

55±8

62±9

72±8†

Female

376 (30.8%)

67 (36.1%)

76 (26.9%)

233 (31.0%)

0

39 (23.9%)†

337 (33.5%)†

Components of the CHADS 2 score

 Congestive heart failure

101 (8.3%)

0

20 (7.1%)

81 (10.8%)†

0

7 (4.3%)

94 (9.4%)†

 Hypertension

634 (51.9%)

0

146 (51.6%)

488 (64.9%)†

0

46 (28.2%)

588 (58.5%)†

 65–4 Years old

443 (36.3%)

94 (50.5%)

102 (36.0%)

247 (32.9%)†

0

63(38.7%)

380 (37.8%)†

 75 Years old or older

438 (35.9%)

0

87 (30.7%)

351 (46.9%)†

0

0

438 (43.6%)†

 Diabetes mellitus

264 (21.6%)

0

30 (10.6%)

234 (31.1%)†

0

8 (4.9%)

256 (25.5%)†

 Prior cerebral ischemia

541 (44.3%)

0

0

541 (71.9%)†

0

0

541 (53.8%)†

 Prior thromboembolism

11 (0.9%)

0

1 (0.4%)

10 (1.3%)

0

0

11 (1.1%)

 Vascular disease

64 (5.2%)

5 (2.7%)

21 (7.4%)

38 (5.1%)

0

0

64 (6.4%)

Comorbidities

 Neoplasm

96 (7.9%)

13 (7.0%)

22 (7.8%)

61 (8.1%)

2 (3.8%)

10 (6.1%)

84 (8.4%)

 Liver cirrhosis

40 (3.3%)

9 (4.8%)

6 (2.1%)

25 (3.3%)

2 (3.8%)

5 (3.1%)

33 (3.3%)

Risk factors

 Hypercholesterolemia

375 (30.7%)

41 (22.0%)

83 (29.3%)

251 (33.4%)†

12 (22.6%)

36 (22.1%)

327 (32.5%)*

 Current smoking

156 (12.8%)

27 (14.5%)

38 (13.4%)

91 (12.1%)

11 (20.8%)

30 (18.4%)

115 (11.4) †

 Alcohol consumption

53 (4.3%)

5 (2.7%)

13 (4.6%)

35 (4.7%)

3 (5.7%)

6 (3.7%)

44 (4.4%)

Systolic blood pressure, mmHg

129±18

123±16

130±18

131±19†

120±15

126±18

130±18†

Diastolic blood pressure, mm Hg

75±11

72±12

76±12

75±11†

72±16

74±11

75±11

Antithrombotic medication

   

†

  

*

 Warfarin alone

873 (71.5%)

141 (75.8%)

191 (67.5%)

541 (71.9%)

38 (71.7%)

120 (73.6%)

715 (71.1%)

 Antiplatelets alone

114 (9.3%)

24 (12.9%)

35 (12.4%)

55 (7.3%)

8 (15.1%)

22 (13.5%)

84 (8.4%)

 Both

234 (19.2%)

21 (11.3%)

57 (20.1%)

156 (20.7%)

7 (13.2%)

21 (12.9%)

206 (20.5%)

  1. Data are medians (interquartile range) for the observation period, means±s.d. for age and blood pressure, and percent of patients for others.
  2. *P<0.05, †P<0.01 among three groups.
  3. CHADS2 scores in high-risk category group; 2: 289 patients, 3: 248 patients, 4: 164 patients, 5: 48 patients, 6: 3 patients.
  4. CHA2DS2-VASc scores in high-risk category group; 2: 240 patients, 3: 260 patients, 4: 231 patients, 5: 165 patients, 6: 89 patients, 7: 18 patients, 8: 2 patients.
Back to article page